BRPI1008939A2 - 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3. - Google Patents

2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.

Info

Publication number: BRPI1008939A2
Authority: BR; Brazil
Prior art keywords: kncq2; mercaptoquinoline; carboxamides; modulators; substituted
Prior art date: 2009-03-12

Application number

BRPI1008939A

Other languages

English (en)

Inventor

Achim Kless

Gregor Bahrenberg

Sven Kühnert

Wolfgang Schröder

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-12

Filing date

2010-03-11

Publication date

2016-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008939(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-11 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2016-03-15 Publication of BRPI1008939A2 publication Critical patent/BRPI1008939A2/pt

Links

CKWKREFECQVBBZ-UHFFFAOYSA-N 2-sulfanylidene-1h-quinoline-3-carboxamide Chemical class C1=CC=C2N=C(S)C(C(=O)N)=CC2=C1 CKWKREFECQVBBZ-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BRPI1008939A 2009-03-12 2010-03-11 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3. BRPI1008939A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09003597		2009-03-12
PCT/EP2010/001509 WO2010102811A1 (de)	2009-03-12	2010-03-11	Substituierte 2-mercaptochinolin-3-carboxamide als kcnq2/3 modulatoren

Publications (1)

Publication Number	Publication Date
BRPI1008939A2 true BRPI1008939A2 (pt)	2016-03-15

Family

ID=40671387

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1008939A BRPI1008939A2 (pt)	2009-03-12	2010-03-11	2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.

Country Status (20)

Country	Link
US (2)	US20100234372A1 (pt)
EP (1)	EP2406229A1 (pt)
JP (1)	JP5727946B2 (pt)
KR (1)	KR20110132590A (pt)
CN (1)	CN102348692A (pt)
AR (1)	AR075824A1 (pt)
AU (1)	AU2010223513B2 (pt)
BR (1)	BRPI1008939A2 (pt)
CA (1)	CA2755004A1 (pt)
CL (1)	CL2011002209A1 (pt)
CO (1)	CO6410292A2 (pt)
EC (1)	ECSP11011348A (pt)
IL (1)	IL214945A0 (pt)
MX (1)	MX2011009369A (pt)
NZ (1)	NZ595625A (pt)
PE (1)	PE20120790A1 (pt)
RU (1)	RU2011141188A (pt)
TW (1)	TWI461197B (pt)
WO (1)	WO2010102811A1 (pt)
ZA (1)	ZA201107444B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3178067B2 (ja)	1991-02-26	2001-06-18	ぺんてる株式会社	スズ−ニッケル二元合金電気めっき液組成物
WO2010102778A2 (de) *	2009-03-10	2010-09-16	Grünenthal GmbH	Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TWI504395B (zh) *	2009-03-10	2015-10-21		Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en)	2009-03-12	2010-11-01	Gruenenthal Gmbh	Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh)	2009-03-12	2015-03-01		The substituted nicotine amide as a KCNQ2 / 3 modifier
AR082732A1 (es)	2010-08-27	2012-12-26	Gruenenthal Gmbh	2-oxiquinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3
WO2012025239A1 (en)	2010-08-27	2012-03-01	Grünenthal GmbH	Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
CA2807886A1 (en)	2010-09-01	2012-03-08	Gruenenthal Gmbh	Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
AU2013329832A1 (en)	2012-10-11	2015-05-28	Grunenthal Gmbh	Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
MX2015006689A (es)	2012-11-28	2015-08-20	Grünenthal GmbH	Carboxamidas especificas como moduladores de kcnq2/3.
US9248122B2 (en)	2012-11-28	2016-02-02	Grünenthal GmbH	Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
CA2892652A1 (en)	2012-11-28	2014-06-05	Grunenthal Gmbh	Heteroquinoline-3-carboxamides as kcnq2/3 modulators
NZ710111A (en)	2013-01-31	2020-08-28	Vertex Pharma	Quinoline and quinoxaline amides as modulators of sodium channels
JP2016511237A (ja)	2013-02-01	2016-04-14	アセチロンファーマシューティカルズインコーポレイテッドＡｃｅｔｙｌｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	選択的ｈｄａｃ３阻害剤
US9139583B2 (en)	2013-02-01	2015-09-22	Acetylon Pharmaceuticals, Inc.	Selective HDAC3 inhibitors
HK1217092A1 (zh)	2013-02-15	2016-12-23	Kala Pharmaceuticals, Inc.	治疗性化合物及其用途
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt)	2013-02-20	2017-07-18	Kala Pharmaceuticals Inc	compostos terapêuticos e usos dos mesmos
KR20160099084A (ko)	2013-11-01	2016-08-19	칼라 파마슈티컬스, 인크.	치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
PH12015000236B1 (en) *	2015-07-06	2024-01-10	Samsung Electronics Co Ltd	Electronic device for providing a calibrated keyboard configuration
CA3036065A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en)	2016-09-08	2020-05-13	Kala Pharmaceuticals, Inc.	CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
JP7120549B2 (ja) *	2016-12-15	2022-08-17	小野薬品工業株式会社	Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
DE102018212006B3 (de) *	2018-07-18	2019-10-31	Universität Greifswald	Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen
EP4580618A2 (en) *	2022-08-30	2025-07-09	Pannex Therapeutics Inc.	Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2706977A1 (de)	1977-02-18	1978-08-24	Hoechst Ag	Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2532939A1 (fr) *	1982-09-13	1984-03-16	Roussel Uclaf	Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de)	1990-10-10	1992-04-16	Bayer Ag	Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
EP0716077A1 (de)	1994-12-08	1996-06-12	Ciba-Geigy Ag	Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (en)	1995-03-01	1996-09-06	Banyu Pharmaceutical Co., Ltd.	Arylthioacetamide derivatives
DE19738616A1 (de)	1997-09-04	1999-03-11	Clariant Gmbh	4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
DE19738615A1 (de) *	1997-09-04	1999-03-11	Clariant Gmbh	Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen
WO2000042026A1 (en) *	1999-01-15	2000-07-20	Novo Nordisk A/S	Non-peptide glp-1 agonists
EP1208085B1 (en)	1999-08-04	2007-12-05	Icagen, Inc.	Benzanilides as potassium channel openers
BR0012934A (pt)	1999-08-04	2003-07-29	Icagen Inc	Processos para a redução de dor e de ansiedade
IL157313A0 (en) *	2001-02-20	2004-02-19	Bristol Myers Squibb Co	Modulators of kcnq potassium channels and uses thereof
HUP0303841A2 (hu)	2001-02-20	2004-03-01	Bristol-Myers Squibb Company	2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk
US6593349B2 (en)	2001-03-19	2003-07-15	Icagen, Inc.	Bisarylamines as potassium channel openers
JP2004526756A (ja) *	2001-04-06	2004-09-02	スミスクラインビーチャムコーポレーション	ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤
JP2005539081A (ja)	2002-09-17	2005-12-22	ファルマシアコーポレイション	芳香族肝臓ｘ受容体モジュレーター
AU2003303484C1 (en)	2002-12-23	2012-06-14	Icagen, Inc.	Quinazolinones as potassium channel modulators
EP1449841A1 (en)	2003-02-19	2004-08-25	Bayer CropScience SA	New fungicidal compounds
AU2004279855A1 (en)	2003-10-08	2005-04-21	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups
CN1950334A (zh)	2004-05-04	2007-04-18	辉瑞有限公司	邻位取代的芳基或杂芳基酰胺化合物
MX341797B (es) *	2004-06-24	2016-09-02	Vertex Pharmaceuticals Incorporated *	Moduladores de transportadores con casete de union con atp.
CA2585490A1 (en)	2004-11-12	2006-05-18	Galapagos Nv	Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
WO2006092143A1 (en)	2005-03-03	2006-09-08	H. Lundbeck A/S	Substituted pyridine derivatives
DE102005038947A1 (de)	2005-05-18	2006-11-30	Grünenthal GmbH	Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
US8133907B2 (en)	2005-07-20	2012-03-13	Eli Lilly And Company	Pyridine derivatives as dipeptedyl peptidase inhibitors
US7915410B2 (en)	2005-09-09	2011-03-29	Bristol-Myers Squibb Company	Acyclic IKur inhibitors
WO2007057447A1 (en)	2005-11-18	2007-05-24	Neurosearch A/S	Novel quinazoline derivatives and their medical use
WO2008011080A2 (en)	2006-07-20	2008-01-24	Amgen Inc.	Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine
CA2658190C (en)	2006-07-20	2013-01-29	Amgen Inc.	Di-amino-substituted heterocyclic compounds and methods of use
US20100022589A1 (en)	2006-07-27	2010-01-28	Mccoull William	Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
DE102006049452A1 (de)	2006-10-17	2008-05-08	Grünenthal GmbH	Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
WO2008066900A1 (en) *	2006-11-28	2008-06-05	Valeant Pharmaceuticals International	1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8563566B2 (en)	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
BRPI0814758A2 (pt)	2007-08-03	2015-03-03	Hoffmann La Roche	Piridinacarboxamida e derivados de benzamida como ligantes taar1
CA2702469A1 (en)	2007-10-19	2009-04-23	Boehringer Ingelheim International Gmbh	Ccr10 antagonists
TWI504395B (zh) *	2009-03-10	2015-10-21		Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
WO2010102778A2 (de) *	2009-03-10	2010-09-16	Grünenthal GmbH	Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TWI475020B (zh) *	2009-03-12	2015-03-01		The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) *	2009-03-12	2010-11-01	Gruenenthal Gmbh	Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators

2010
- 2010-02-24 TW TW099105238A patent/TWI461197B/zh not_active IP Right Cessation
- 2010-03-10 US US12/720,864 patent/US20100234372A1/en not_active Abandoned
- 2010-03-11 RU RU2011141188/04A patent/RU2011141188A/ru not_active Application Discontinuation
- 2010-03-11 PE PE2011001567A patent/PE20120790A1/es not_active Application Discontinuation
- 2010-03-11 WO PCT/EP2010/001509 patent/WO2010102811A1/de not_active Ceased
- 2010-03-11 KR KR1020117023788A patent/KR20110132590A/ko not_active Withdrawn
- 2010-03-11 BR BRPI1008939A patent/BRPI1008939A2/pt not_active IP Right Cessation
- 2010-03-11 MX MX2011009369A patent/MX2011009369A/es active IP Right Grant
- 2010-03-11 NZ NZ595625A patent/NZ595625A/xx not_active IP Right Cessation
- 2010-03-11 EP EP10708726A patent/EP2406229A1/de not_active Withdrawn
- 2010-03-11 CN CN2010800112967A patent/CN102348692A/zh active Pending
- 2010-03-11 JP JP2011553352A patent/JP5727946B2/ja not_active Expired - Fee Related
- 2010-03-11 AU AU2010223513A patent/AU2010223513B2/en not_active Ceased
- 2010-03-11 CA CA2755004A patent/CA2755004A1/en not_active Abandoned
- 2010-03-12 AR ARP100100777A patent/AR075824A1/es not_active Application Discontinuation
2011
- 2011-08-24 CO CO11107978A patent/CO6410292A2/es not_active Application Discontinuation
- 2011-09-04 IL IL214945A patent/IL214945A0/en unknown
- 2011-09-08 CL CL2011002209A patent/CL2011002209A1/es unknown
- 2011-09-23 EC EC2011011348A patent/ECSP11011348A/es unknown
- 2011-10-11 ZA ZA2011/07444A patent/ZA201107444B/en unknown
2012
- 2012-06-15 US US13/523,955 patent/US8399673B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2010223513B2 (en)	2014-12-04
TW201034670A (en)	2010-10-01
RU2011141188A (ru)	2013-04-20
ECSP11011348A (es)	2011-10-31
MX2011009369A (es)	2011-09-27
JP2012520249A (ja)	2012-09-06
NZ595625A (en)	2012-10-26
CN102348692A (zh)	2012-02-08
US20100234372A1 (en)	2010-09-16
TWI461197B (zh)	2014-11-21
US20120252841A1 (en)	2012-10-04
CL2011002209A1 (es)	2012-02-10
AU2010223513A1 (en)	2011-11-03
KR20110132590A (ko)	2011-12-08
AR075824A1 (es)	2011-04-27
PE20120790A1 (es)	2012-07-08
US8399673B2 (en)	2013-03-19
IL214945A0 (en)	2011-11-30
CO6410292A2 (es)	2012-03-30
JP5727946B2 (ja)	2015-06-03
WO2010102811A1 (de)	2010-09-16
EP2406229A1 (de)	2012-01-18
ZA201107444B (en)	2012-06-27
CA2755004A1 (en)	2010-09-16

Legal Events

Date	Code	Title	Description
2016-07-26	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 6A ANUIDADE. PAGAR RESTAURACAO.
2016-10-04	B08H	Application fees: decision cancelled [chapter 8.8 patent gazette]	Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2377 DE26/07/2016.
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-06-19	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-12-04	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE RPI 2476 DE 19/062018

Publication	Publication Date	Title
BRPI1008939A2 (pt)	2016-03-15	2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
BRPI1008949A2 (pt)	2015-09-01	Cetoenóis haloalquilmetilenóxi-fenil-substituídos.
BRPI1009415A2 (pt)	2016-03-01	escova de dentes.
BRPI1010301A2 (pt)	2016-03-15	composição.
BRPI0919295A2 (pt)	2015-12-15	1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI1007047A2 (pt)	2015-08-18	Biorrefino irganosolv de cana-de-açúcar inteira.
CU24152B1 (es)	2016-02-29	1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
BRPI0921327A2 (pt)	2015-08-25	Combinação de herbicida-protetor
BRPI0917980A2 (pt)	2015-11-17	subcanalização com aumento de potência
BRPI0919898A2 (pt)	2016-02-16	4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3
BRPI1008948A2 (pt)	2016-03-15	nicotinamida substituída como moduladores kcnq2/3.
UY33125A (es)	2011-07-29	Diaza-espiro-[5,5]-undecanos
BRPI1014802A2 (pt)	2016-04-05	pró-fármacos de triptolida.
CU23870B1 (es)	2013-03-27	Derivados de ciclopropilamida como moduladores h3
BRPI1009428A2 (pt)	2016-03-01	3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
BRPI1014339A2 (pt)	2016-07-26	composição de piche.
BRPI1011460A2 (pt)	2015-08-25	Composição desinfetante.
BRPI1014388A2 (pt)	2016-04-05	preparação de sólido.
IT1396487B1 (it)	2012-12-14	Convogliatore.
BRPI1013157A2 (pt)	2016-04-05	meio de fixação.
EP2259958A4 (en)	2012-02-08	LINKAGE
BRPI1009519A2 (pt)	2016-03-15	3-amino-2-mercaptoquinolina substituída como modulador de kcnq2/3.
BRPI1016192A2 (pt)	2016-04-19	derivados de soxazol.
EP2459573A4 (en)	2014-08-27	SUBSTITUTED 1,2-AZABORIN HETEROCYCLES
FR2947857B1 (fr)	2012-03-30	Agencement de deshuileur